Status | Study |
Recruiting |
Study Name: Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Condition: Hyperprolactinemia Prolactinoma Date: 2017-01-30 Interventions: Drug: Ropinirole |
Recruiting |
Study Name: PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon Condition: Pituitary Tumor Date: 2016-07-27 |
Recruiting |
Study Name: Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus Condition: Invasive Prolactinomas Involving the Cavernous Sinus Date: 2015-08-15 |
Recruiting |
Study Name: Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Condition: Pituitary Neoplasms Prolactinoma Date: 2013-01-22 Interventions: Other: Educational Intervention A brochure and access to a website including videos that contain detaile |
Active, not recruiting |
Study Name: Rhinological Outcomes in Endonasal Pituitary Surgery Condition: Pituitary Neoplasm Pituitary Adenoma Date: 2012-01-03 |
Completed |
Study Name: Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Condition: Non-functioning Pituitary Adenomas Prolactinomas Date: 2011-09-18 Interventions: Drug: Pasireotide |
Recruiting |
Study Name: Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients Condition: Hyperprolactinoma Date: 2011-04-18 Interventions: Drug: Curcumin Curcumin is prescribed to new cases of hyperprolactinoma |
Recruiting |
Study Name: Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Condition: Macroprolactinoma Date: 2010-06-01 Interventions: Drug: Cabergoline |
Terminated |
Study Name: Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Condition: Childhood Atypical Teratoid/Rhabdoid Tumor Childhood Central Nervous System Choriocarcinoma Date: 2010-03-16 Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097 |
Recruiting |
Study Name: Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Condition: Pituitary Adenomas Prolactinomas Date: 2009-07-14 Interventions: Drug: Lapatinib All participants will be asked to take Lapatinib daily for six months during the researc |